Shots:

• The approval is based on three clinical trials involves assessing Trilaciclib +carboplatin/etoposide (+/- atezolizumab) and topotecan CT regimens in patients with ES-SCLC. 90% of all patients with ES-SCLC will receive at least one of these regimens
• The result show reductions in the incidence and duration of severe neutropenia- positive impact on RBC transfusions and other myeloprotective measures- and impacted anemia and the need for rescue interventions such as growth factors
• Trilaciclib is the 1st therapy designed to help protect bone marrow during CT and has received the US FDA’s BTD in 2019 and expected to be commercially available in Mar’2021

 ­ Ref: Globenewswire | Image: Linkedin